Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-01-14

Clinical Trial Update: Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sunitinib malate to sorafenib in inoperable hepatocellular carcinoma was terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)
  • Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: TERMINATED | Results posted: 2013-01-14